The "Duty to Warn" a Patient's Family Members About Hereditary Disease Risks
Top Cited Papers
- 22 September 2004
- journal article
- health law-and-ethics
- Published by American Medical Association (AMA) in JAMA
- Vol. 292 (12) , 1469-1473
- https://doi.org/10.1001/jama.292.12.1469
Abstract
Review from JAMA — The Duty to Warn a Patient's Family Members About Hereditary Disease Risks — Genetic tests for adult-onset disorders, including common forms of cancer, are now commercially available, and tests for genetic polymorphisms that predict drug effects or toxicity after treatment are under development. For each of these circumstances, testing of 1 individual may imply an increased risk to his/her relative.The obligation, if any, to warn family members of the identification of a genetic mutation has generated concerns regarding the conflict between the physician's ethical obligations to respect the privacy of genetic information vs the potential liabilities resulting from the physician's failure to notify at-risk relatives. A duty to warn relatives about risks due to some infectious agents has been assumed by state and local health agencies, and the duty to breach confidentiality to warn of imminent harm has been the subject of case law.In general, the special nature of genetic tests has been viewed as a barrier to physicians' breaching the confidentiality of personal genetic information. However, the failure to warn family members about hereditary disease risks has already resulted in 3 lawsuits against physicians in the United States.While the findings of case law and the state and federal statutes that bear on the issue of "duty to warn" of inherited health risk are still being defined, we believe that health care professionals have a responsibility to encourage but not to coerce the sharing of genetic information in families, while respecting the boundaries imposed by the law and by the ethical practice of medicine.Keywords
This publication has 11 references indexed in Scilit:
- Pharmacogenetic Study of Statin Therapy and Cholesterol ReductionJAMA, 2004
- Medical geneticists' duty to warn at‐risk relatives for genetic diseaseAmerican Journal of Medical Genetics Part A, 2003
- Duty to warn at‐risk relatives for genetic disease: Genetic counselors' clinical experienceAmerican Journal Of Medical Genetics Part C-Seminars In Medical Genetics, 2002
- Genetic Test Evaluation: Information Needs of Clinicians, Policy Makers, and the PublicAmerican Journal of Epidemiology, 2002
- Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2MutationNew England Journal of Medicine, 2002
- Primary Chemoprevention of Familial Adenomatous Polyposis with SulindacNew England Journal of Medicine, 2002
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancerGastroenterology, 1995
- Clinical Screening as Compared with DNA Analysis in Families with Multiple Endocrine Neoplasia Type 2ANew England Journal of Medicine, 1994
- Predictive DNA Testing and Prophylactic Thyroidectomy in Patients at Risk for Multiple Endocrine Neoplasia Type 2AAnnals of Surgery, 1994